THEOCLEAR-200 Drug Patent Profile
✉ Email this page to a colleague
When do Theoclear-200 patents expire, and when can generic versions of Theoclear-200 launch?
Theoclear-200 is a drug marketed by Cent Pharms and is included in one NDA.
The generic ingredient in THEOCLEAR-200 is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theoclear-200
A generic version of THEOCLEAR-200 was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for THEOCLEAR-200?
- What are the global sales for THEOCLEAR-200?
- What is Average Wholesale Price for THEOCLEAR-200?
Summary for THEOCLEAR-200
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 171 |
| Patent Applications: | 6,518 |
| DailyMed Link: | THEOCLEAR-200 at DailyMed |
US Patents and Regulatory Information for THEOCLEAR-200
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cent Pharms | THEOCLEAR-200 | theophylline | TABLET;ORAL | 085353-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
